🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. PYX-201

    Pyxis Oncology

    Solid Tumor

    phase 1 small molecule active

    1 trial

  2. Palbociclib + Taselisib / Pictilisib

    United Therapeutics Europe Ltd

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  3. Panobinostat (LBH589), Carboplatin and Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  4. Pevonedistat

    Takeda

    Advanced Solid Tumors, Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  5. Pevonedistat

    Takeda

    Advanced Solid Neoplasm

    phase 1 small molecule completed

    2 trials

  6. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  7. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Olema Pharmaceuticals

    Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  8. Phase 1 Study of PYX-106 in Solid Tumors

    Pyxis Oncology

    Solid Tumors

    phase 1 other active

    1 trial

  9. Phase 1 Study of PYX-201 in Solid Tumors

    Pyxis Oncology

    Advanced solid tumors

    phase 1 other active

    1 trial

  10. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  11. Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors.

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  12. Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 1 other active

    1 trial

  13. Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors

    Novartis Pharmaceuticals

    Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway

    phase 1 other active

    1 trial

  14. Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors

    Lacuna Pharma Pty Ltd

    Advanced solid tumors

    phase 1 other active

    1 trial

  15. RAD 001 in combination with Caelyx

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  16. REGN421(SAR153192)

    Regeneron UK Limited

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  17. RMC-4630

    Revolution Medicines

    Solid Tumors

    phase 1 small molecule active

    1 trial

  18. RMC-5552

    Revolution Medicines

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  19. Radiation: 18F-AlF-FAPi-04

    Sichuan Provincial People's Hospital

    Tumor, Solid

    phase 1 small molecule active

    1 trial

  20. SGT-212

    Solid Biosciences

    Friedreich's Ataxia (FA)

    phase 1 small molecule active

    1 trial

  21. SGT-501

    Solid Biosciences

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 1 small molecule active

    1 trial

  22. SIBP-A13 formulation for injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  23. SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

    Lacuna Pharma Pty Ltd

    small cell lung cancer, non-smallcell lung cancer, colorectal cancer, breast cancer, Pancreatic cancer and gastric cancer

    phase 1 other active

    1 trial

  24. SRF617

    Coherus Oncology

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources